Navigation Links
Celtic Pharma Holdings Announces Investment in Novacta Biosystems Limited
Date:7/5/2009

ST PETER PORT, Guernsey and LONDON, July 6 /PRNewswire/ --

- GBP13.1 Million Funding to Drive Novel Antibiotics Platform Addressing Areas of Major Unmet Need, Including Hospital Acquired Infections C. Difficile and MRSA

Celtic Pharma Holdings Advisors LLP ("CPHA"), the advisor to the second Celtic Pharma fund, Celtic Pharma Holdings II LP ("CP2"), today announces its investment in a majority shareholding in Novacta Biosystems Limited ("Novacta"), which is developing a portfolio of antibiotics. The total being raised is GBP13.1m ($21.6m), payable against pre-agreed milestones. As part of this investment certain existing investors are re-investing.

Novacta is a UK-based company developing novel, naturally-derived products known as 'lantibiotics' as potential drugs. Lantibiotics have potent anti-infective properties but have historically been underexploited owing to a lack of research tools, a challenge that Novacta has successfully addressed through its proprietary technology platform. The most advanced programme will enter the clinic next year to treat infections caused by Clostridium difficile ("C. difficile"). The Wellcome Trust has provided in the order of GBP4m of translational funding to Novacta since 2004 for the development of the platform technology and more recently the C. difficile programme.

New anti-infective drugs are needed to target C. difficile without depleting other beneficial bacteria in the gut and preclinical data show that Novacta's lead lantibiotics selectively kill C. difficile with less disturbance of normal gut bacteria than seen with existing drugs. C. difficile infections (CDIs) are a serious problem: the number of cases grew by 22 percent in the UK last year, accounting for twice as many deaths as MRSA.

Novacta's pipeline also includes programmes targeting other areas of unmet medical need in bacterial infection. These include novel prom
'/>"/>

SOURCE Celtic Pharma Holdings Advisors LLP
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Neurobiological Technologies Partner, Celtic Pharma, Provides Update on XERECEPT(R) Clinical Program and Planned Sale in 2009
2. iCardiac Selected by Top 10 Pharmaceutical Company
3. WuXi PharmaTech Receives Award from BASF
4. Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease
5. NeoStem Raises Additional Funds from Principals of Suzhou Erye Pharmaceuticals Company Ltd. and U.S. Institutional and Private Investors, Bringing the Total Recent Financings to Over $15 Million; Funds Will Support Expansion Activities in the United State
6. Particle Sciences and Microfluidics Collaborate to Share Formulation and Nanotechnology Expertise for Pharmaceutical Drug Product Development, Analysis and Commercialization
7. Rib-X Pharmaceuticals, Inc. Appoints Dr. Russell Greig to Board of Directors
8. OncoGenex Pharmaceuticals Added to Russell Indexes
9. Asia Debut for Money-Saving Pharma-Packaging Machines from Ireland
10. Pharmaxis Closes Share Purchase Plan
11. ADVENTRX Pharmaceuticals Announces Plans for Remainder of 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015  With over 60,000 customers across the globe, ISN improves the ... hiring organizations with more than 60,000 safe and reliable contractors in over 80 countries. ... ... Over 60,000 ... Headquartered in Dallas, TX , ...
(Date:7/30/2015)... ... July 30, 2015 , ... As part of its 2015 growth plan and as a follow ... service business units, Whitehouse Laboratories is pleased to announce that it has begun construction ... Center of Excellence and will be strictly dedicated to basic USP 51, USP 61, and ...
(Date:7/29/2015)... , July 30, 2015 According ... Market - Growth, Trends & Forecasts (2015-2020), , published by ... US$ 30.25 billion by the end of 2020, with ... accounting for more than 40% of the global market size. ... at a CAGR of 13.7% during the period of (2015-2020). ...
(Date:7/29/2015)...  HealthSouth Corporation (NYSE: HLS ), ... healthcare services, offering both facility-based and home-based post-acute ... the second quarter ended June 30, 2015. ... volume growth in both segments and an 11.0% ... President and Chief Executive Officer of HealthSouth. "While ...
Breaking Biology Technology:ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3Whitehouse Labs Formally Announces Plans to Open a Microbiological Laboratory 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 3HealthSouth Reports Results for Second Quarter 2015 2HealthSouth Reports Results for Second Quarter 2015 3HealthSouth Reports Results for Second Quarter 2015 4HealthSouth Reports Results for Second Quarter 2015 5HealthSouth Reports Results for Second Quarter 2015 6HealthSouth Reports Results for Second Quarter 2015 7HealthSouth Reports Results for Second Quarter 2015 8HealthSouth Reports Results for Second Quarter 2015 9HealthSouth Reports Results for Second Quarter 2015 10HealthSouth Reports Results for Second Quarter 2015 11HealthSouth Reports Results for Second Quarter 2015 12HealthSouth Reports Results for Second Quarter 2015 13HealthSouth Reports Results for Second Quarter 2015 14HealthSouth Reports Results for Second Quarter 2015 15HealthSouth Reports Results for Second Quarter 2015 16HealthSouth Reports Results for Second Quarter 2015 17HealthSouth Reports Results for Second Quarter 2015 18HealthSouth Reports Results for Second Quarter 2015 19HealthSouth Reports Results for Second Quarter 2015 20HealthSouth Reports Results for Second Quarter 2015 21HealthSouth Reports Results for Second Quarter 2015 22HealthSouth Reports Results for Second Quarter 2015 23HealthSouth Reports Results for Second Quarter 2015 24HealthSouth Reports Results for Second Quarter 2015 25HealthSouth Reports Results for Second Quarter 2015 26HealthSouth Reports Results for Second Quarter 2015 27HealthSouth Reports Results for Second Quarter 2015 28HealthSouth Reports Results for Second Quarter 2015 29HealthSouth Reports Results for Second Quarter 2015 30HealthSouth Reports Results for Second Quarter 2015 31
... 10, 2010 Ramius V&O Acquisition LLC, a subsidiary ... has sent a letter to the Board of Directors ... outlining its willingness to acquire all of Cypress, outstanding ... share.  The offer is conditioned upon Cypress commencing exclusive ...
... 10, 2010 Pfizer Inc. (NYSE: PFE ... safety, it is voluntarily withdrawing Thelin® (sitaxentan) for the ... it is approved (the European Union, Canada and Australia). ... worldwide. (Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO) Pfizer,s ...
... will help UK athletes reach the top of their ... the UK,s high performance sports agency, has reached an ... edge technology developed by Argento Diagnostics to improve training ... to monitor various proteins which reveal details about the ...
Cached Biology Technology:Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share 2Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share 3Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share 4Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share 5Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share 6Pfizer Stops Clinical Trials of Thelin® and Initiates Voluntary Product Withdrawal in the Interest of Patient Safety 2Pfizer Stops Clinical Trials of Thelin® and Initiates Voluntary Product Withdrawal in the Interest of Patient Safety 3Medical science helps UK athletes reach peak performance 2Medical science helps UK athletes reach peak performance 3
(Date:7/31/2015)... Die 10. internationale Konferenz zu Genomik (ICG-10, ... vom 22. bis 25. Oktober 2015 in ... Die Konferenz feiert in diesem Jahr ihr ... ICG weltweit zu einem der einflussreichsten jährlichen Treffen ... dynamischsten, enthusiastischsten und angenehmsten wissenschaftlichen Zusammentreffen. ...
(Date:7/31/2015)... China , July 31, 2015 The 10 ... will be held by BGI from October 22-25, 2015, in ... The conference is celebrating its 10 th anniversary ... one of the world,s most influential annual meetings in the ... and enjoyable scientific gatherings. ICG-10 focuses on ...
(Date:7/27/2015)... SAN JOSE, Calif. , July 27, 2015 ... leading developer of human interface solutions, today announced ... ClearPad ® touchscreen solution for its stylish ... controller for its proven reliability, low power and ... with a wet finger. Huawei designers also required ...
Breaking Biology News(10 mins):Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3The 10th International Conference on Genomics (ICG-10) to Open in October 2Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3
... At some point this year, after NASA,s rover Curiosity has ... infrared light at a rock or soil sample. This will ... a plume of ionized gas or plasma, which will be ... Mars rovers, however, will be able to do even more. ...
... 1, 2012 Probing the largely unexplored question of ... have discovered that by mimicking nature, a robotic fish ... Through a series of experiments, researchers from Polytechnic Institute ... of collective animal behavior, including learning how robots might ...
... Philadelphia, PA, March 1, 2012 Down syndrome (DS) ... children arising as a consequence of a chromosomal abnormality. ... of chromosome 21, instead of the usual two. It ... dysfunction that can range from mild to severe but ...
Cached Biology News:LAMIS -- a green chemistry alternative for laser spectroscopy 2LAMIS -- a green chemistry alternative for laser spectroscopy 3LAMIS -- a green chemistry alternative for laser spectroscopy 4What makes a robot fish attractive? (Hint: It's in the moves) 2Understanding and treating the cognitive dysfunction of Down syndrome and Alzheimer's disease 2
... Monitoring Kit measures adenosine triphosphate ... and a dynamic range. Based ... assay measures ATP in bacterial, ... a concentration range of 10-11 ...
... series of refrigerated cold traps offers a ... low volatility/aqueous solvents or high volatility solvents. ... vacuum concentrators/centrifugal evaporators. Also used for maintaining ... as used in electron microscopes. Can be ...
... Trap is specifically designed for efficient ... as DMSO and DMF in the ... refrigeration system set at -5 o ... DMSO, while completely eliminating the risk ...
Black 96 Well Plate EB, RE Bottom...
Biology Products: